Thoracic Malignancies
Clinical Research

Get to Know Dr. Nathan Pennell 

Dr. Nathan Pennell is a medical oncologist at the Taussig Cancer Institute at the Cleveland Clinic. He focuses on thoracic malignancies, with a particular interest in mesothelioma, and was appointed director of the lung cancer medical oncology program in 2010. He is a professor of medicine at the Cleveland Clinic Lerner College of Medicine.

Pennell achieved a Ph.D. in neuroscience in 1998, and graduated from the University of Florida School of Medicine in 2002. He has been at the Cleveland Clinic since 2008, with research interests that include mesothelioma treatment and clinical trials using novel therapies.

He completed his internship and residency in Boston at Brigham and Women’s Hospital in 2005 and finished his fellowship in 2007 at the nearby Dana-Farber Cancer Institute.

Pennell completed additional training at the Harvard T.H. Chan School of Public Health in the clinical effectiveness program.

Specialties of Dr. Nathan Pennell

  • Pleural and lung cancer
  • Research

Dr. Nathan Pennell’s Experience and Medical Education

  • Taussig Cancer Institute
  • University of Florida College of Medicine (M.D.)
  • Brigham and Women’s Hospital (Residency)
  • Dana-Farber Cancer Institute (Fellowship)

Awards and Certifications

  • Board certified in medical oncology
  • Board certified in internal medicine

Publications of Dr. Nathan Pennell

  • Drilon, A. et al. (2020, August 27). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer. New England Journal of Medicine.
  • Rivera, D.R. et al. (2020, July 22). Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery.
  • Zagouras, A. et al. (2020, June 21). Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade Induced Diabetes. Oncologist.
  • Kuderer, N.M. et al. (2020, June 20). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet.
  • Choi, H. & Pennell, N.A. (2020, May). Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening. Oncologist.